Compare STTK & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STTK | CBIO |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.6M | 507.1M |
| IPO Year | 2020 | 2013 |
| Metric | STTK | CBIO |
|---|---|---|
| Price | $4.55 | $12.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $15.40 | ★ $32.33 |
| AVG Volume (30 Days) | ★ 841.6K | 195.3K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000.00 | $18,500.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.28 | $37.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $8.72 |
| 52 Week High | $8.33 | $27.41 |
| Indicator | STTK | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 43.44 |
| Support Level | $4.38 | $11.78 |
| Resistance Level | $7.66 | $13.54 |
| Average True Range (ATR) | 0.39 | 1.10 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 14.29 | 20.31 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.